Press Releases
Date Title and Summary View
Jun 1, 2017 SAN DIEGO, June 01, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) have each issued a patent covering the Company's product candidate sparsentan, which is advancing to Phase 3 clinical development for the treatment of focal segm...
May 25, 2017 Subgroup analysis from Phase 2 DUET study of sparsentan in FSGS to be presented at ERA-EDTA PKAN-ADL scale in Phase 3 FORT study of RE-024 in PKAN to be highlighted at MDS SAN DIEGO, May 25, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced upcoming presentations related to its late-stage development programs, sparsenta...
May 23, 2017 SAN DIEGO, May 23, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Jefferies 2017 Global Healthcare Conference in New York City on Tuesday, June 6, 2017 at 3:30 p.m. ET. A live webcast of the presentation will be available at http://ir.retrophin.com/eve...
May 4, 2017 Phase 3 FORT study of RE-024 in PKAN to begin dosing mid-2017 Protocol development underway for pivotal Phase 3 trial of sparsentan in FSGSFirst quarter revenues rose 16 percent to $34 millionSAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today reported its first quarter 2017 financial results and provided a corporat...
Apr 20, 2017 SAN DIEGO, April 20, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report first quarter 2017 financial results on Thursday, May 4, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p...
Apr 12, 2017 SAN DIEGO, April 12, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Ron Squarer to the Company's Board of Directors, effective immediately. Mr. Squarer is chief executive officer and a director of Array BioPharma Inc., a biopharmaceutical company focused on the discovery, development, and commercializati...
Mar 23, 2017 SAN DIEGO, March 23, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of John A. Orwin to the Company's Board of Directors, effective immediately. Mr. Orwin currently serves as chief executive officer of Relypsa, Inc., a biopharmaceutical company focused on developing treatments for patients with conditions t...
Mar 7, 2017 SAN DIEGO, March 07, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Barclays Global Healthcare Conference in Miami on Wednesday, March 15, 2017 at 2:05 p.m. ET. A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm ...
Mar 1, 2017 Phase 3 trial of sparsentan in FSGS to initiate in second half of 2017; Interim analysis of proteinuria to serve as basis for NDA filing for accelerated approval Full year 2016 revenue grew 34% over 2015 to $134 million Conference call today at 5:00 p.m. ET SAN DIEGO, March 01, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today p...
Feb 28, 2017
Page:
1
... NextLast
= add release to Briefcase